Last edition
News about "zocilurtatug pelitecan"
Zai Lab Secures EMA Orphan Drug Status for Zoci in Pulmonary Neuroendocrine Carcinomas
Zai Lab has received EMA Orphan Drug Designation (ODD) for zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas. The designation recognises promising clinical data suggesting potential benefits over existing therapies for patients with relapsed or refractory extensive-stage Small Cell Lung Cancer (SCLC).
Zocilurtatug Pelitecan | 17/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members